Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NNMT | P40261 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13828406 | 0.83 | POLB (0.33) | ALDH1A1NPSR1MAPTPOLBKMT2A | |
| SCHEMBL10126430 | 0.81 | POLB (0.44) | ALDH1A1NPSR1MAPTTSHRPOLB | |
| SCHEMBL13780200 | 0.74 | KDM4E (0.40) | ALDH1A1NPSR1MAPTPOLBKMT2A | |
| SCHEMBL13780204 | 0.69 | POLB (0.53) | ALDH1A1NPSR1MAPTPOLBKMT2A | |
| SCHEMBL13828343 | 0.69 | PDPK1 (0.38) | POLBNNMT | |
| SCHEMBL13780203 | 0.69 | POLB (0.34) | ALDH1A1NPSR1MAPTTSHRPOLB | |
| SCHEMBL14385078 | 0.69 | POLB (0.46) | ALDH1A1MAPTPOLBKMT2AHTT | |
| SCHEMBL3904880 | 0.69 | NNMT (0.50) | ALDH1A1MAPTPOLBKMT2AHTT | |
| SCHEMBL353805 | 0.69 | PDK2 (0.43) | ALDH1A1NPSR1MAPTTSHRPOLB | |
| SCHEMBL13828336 | 0.68 | GFER (0.33) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1970373-A1 | ALICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | CCR4, CCR1, HRH4 | ALDH1A1 1767/4885NPSR1 2574/4885MAPT 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.